Login using

You can login by using one of your existing accounts.

We will be provided with an authorization token (please note: passwords are not shared with us) and will sync your accounts for you. This means that you will not need to remember your user name and password in the future and you will be able to login with the account you choose to sync, with the click of a button.

This section has no chief editors.

Pediatric oncology has experienced great successes in the last 40 years, but daunting challenges must be overcome if these successes are to continue. Very few therapies used to treat childhood cancer today are targeted in nature and as a result, cure is often accompanied by significant acute and long-term toxicities. Continued improvement in outcomes requires development of targeted therapies that are more effective and less toxic. We must learn how to effectively and safely integrate targeted therapies such as small molecules and immunotherapy into cytotoxic regimens to improve outcomes and/or develop these as stand-alone therapies for diseases and subgroups that have not benefited from dose intensive approaches. Effective therapies must also be made available to patients in the developing world, as regimens that are tolerable and effective in these settings.
The aim of Pediatric Oncology is to help address these challenges by publishing quality basic science, translational studies and clinical trials in the field of pediatric oncology. In addition to primary research papers, we welcome focused reviews on recent advances and commentaries on controversial or emerging concepts. Our goal is to provide fair and rapid peer review in order to publish scientific advances for the benefit of all members of the pediatric oncology community, from basic scientists, to clinical researchers, to caregivers.
Pediatric Oncology does not publish case reports.

All manuscripts must be submitted directly to the section Pediatric Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.

Articles published in the section Pediatric Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology and Pediatrics.